People who have received the Covid-19 vaccine from Johnson & Johnson may benefit from a booster dose of Pfizer or Moderna, preliminary results from a US study published Wednesday showed.
The study, funded by the National Institutes of Health (NIH), was eagerly awaited in the United States as it examined the possibility of “mixing” vaccines – using a vaccine different from the initial doses for the booster – which is currently not allowed in the country.
The study was conducted on 458 adults who had been vaccinated with one of three brands approved in the United States (Pfizer, Moderna, or J&J) for at least 12 weeks.
These three groups were each divided into three new groups to receive one of the available booster vaccines. The nine groups consisted of around 50 people each.
The researchers then analyzed the antibody levels 15 days after the booster.
For people initially inoculated with J&J, antibody levels were four times higher after a J&J booster, 35 times higher after a Pfizer booster, and 76 times higher after a Moderna booster.
And antibody levels for those who initially received Moderna injections were higher “regardless of the booster vaccine given,” compared to those who initially received Pfizer or J&J, according to the study.
In addition, “no safety problem has been identified” after the administration of booster doses, he noted.
The study, which has not yet been peer-reviewed, has several limitations, however.
The number of participants was small and the immune response could evolve over time, beyond the 15 days observed during the study.
“It’s important not to get too carried away with the results,” tweeted Peter Hotez, professor at Baylor College of Medicine.
The results of testing on a second J&J recall run by the company itself were “impressive,” he said.
The NIH study is expected to feed into discussions by a U.S. Food and Drug Administration (FDA) expert panel, which is expected to review Moderna and J&J booster dose requests on Thursday and Friday, respectively.
A Pfizer recall has already been approved in the United States for certain populations, such as people 65 years of age or older, adults with high-risk medical conditions, and those in jobs where they are frequently exposed to the coronavirus.
(Except for the title, this story was not edited by The Bharat Express News staff and is posted Platforms.)